Mu opioid receptors (MOR, encoded by OPRM1) are inhibitory Gi/o-coupled G protein-coupled receptors widely distributed throughout the central nervous system. These receptors are the primary target for endogenous opioid peptides (endorphins, enkephalins) and exogenous opioid analgesics (morphine, heroin, fentanyl). MOR neurons play critical roles in pain modulation, reward processing, autonomic function, immune modulation, and neuroendocrine regulation. Dysregulation of MOR signaling is implicated in chronic pain, opioid use disorder, Parkinson's disease, Alzheimer's disease, and various neuropsychiatric conditions.
| Property |
Value |
| Category |
Opioid Receptor Neurons |
| Location |
Thalamus, Periaqueductal gray, Amygdala, NAcc, Cortex |
| Receptor Type |
MOR (OPRM1) |
| Signaling |
Gi-coupled, inhibitory |
| Gene |
OPRM1 (chromosome 6q24-q25) |
| Protein |
Mu opioid receptor (MOR-1) |
The mu opioid receptor is a 7-transmembrane domain GPCR belonging to the opioid receptor family (μ, δ, κ, NOP). MOR exhibits the highest affinity for endogenous β-endorphin and enkephalins, as well as classical opioid analgesics.
- Family: Opioid receptors (μ, δ, κ, NOP)
- G protein: Gi/o (inhibitory)
- Second messenger: cAMP decreases, K+ channels open, Ca2+ channels close
- Isoforms: Multiple splice variants (MOR-1A, MOR-1B, etc.) with distinct distributions
- Structure: Class A GPCR with distinct opioid-binding pocket
MOR activation triggers multiple inhibitory signaling cascades:
- Adenylyl cyclase inhibition: Gi/o protein inhibition of adenylyl cyclase reduces cAMP production, counteracting excitatory signaling
- ** potassium channel activation**: Activation of GIRK (G protein-activated inward rectifier K+) channels hyperpolarizes neurons
- Voltage-gated calcium channel inhibition: N-type VGCC inhibition reduces neurotransmitter release
- β-arrestin pathways: β-arrestin recruitment leads to receptor internalization and can mediate distinct signaling cascades
MOR is extensively distributed throughout the neuraxis:
- Periaqueductal gray (PAG): High density, primary site of opioid analgesia
- Rostral ventral medulla (RVM): Descending pain modulation
- Thalamus: Medial and intralaminar nuclei, pain perception
- Amygdala: Central nucleus, emotional and fear responses
- Hippocampus: CA1-3 regions, memory and spatial processing
- Cortex: Layer 5 pyramidal neurons, higher-order processing
- Nucleus accumbens: Shell region, reward and motivation
- Ventral tegmental area (VTA): GABAergic interneurons, reward circuitry
- Hypothalamus: Preoptic area and arcuate nucleus, neuroendocrine control
- Spinal cord: Substantia gelatinosa (lamina II), pain transmission
MOR neurons are central to endogenous and exogenous opioid analgesia:
- Supraspinal analgesia: MOR in PAG and RVM activate descending inhibitory pathways to the spinal cord
- Spinal analgesia: MOR on primary afferent terminals and spinal interneurons inhibit nociceptive transmission
- Peripheral analgesia: MOR on peripheral sensory nerve endings
- Emotional component: MOR in amygdala modulates affective dimension of pain
The analgesia mechanism involves:
- Hyperpolarization of pain-transmitting neurons
- Reduced glutamate release from primary afferents
- Enhanced GABAergic inhibition of pain pathways
- Activation of descending inhibitory serotonergic and noradrenergic pathways 1
¶ Reward and Addiction
MOR in the mesolimbic dopamine system is crucial for opioid reward and addiction:
- VTA GABAergic interneurons: MOR inhibition disinhibits VTA dopamine neurons
- Nucleus accumbens shell: MOR on medium spiny neurons modulates reward processing
- Conditioned place preference: MOR activation is sufficient to produce place preference
- Withdrawal and dependence: Chronic MOR activation leads to compensatory upregulation of adenylyl cyclase (adenylyl cyclase superactivation)
¶ Autonomic and Neuroendocrine Regulation
- Respiratory control: MOR in medulla oblongata regulates breathing; MOR activation causes respiratory depression (major cause of opioid overdose death)
- Miosis: MOR in Edinger-Westphal nucleus constricts pupils
- Gastrointestinal motility: MOR in enteric nervous system inhibits GI transit (constipation)
- HPA axis: MOR modulates hypothalamic CRH and pituitary ACTH release
- Thermoregulation: MOR affects body temperature regulation
- Neuroimmune signaling: MOR on glial cells modulates neuroinflammation
- Peripheral immunity: MOR affects lymphocyte function and cytokine production
- Neuroprotection: MOR activation can have neuroprotective effects through anti-inflammatory mechanisms
- Motor complications: MOR dysregulation in basal ganglia contributes to levodopa-induced dyskinesias
- Pain: MOR agonists can treat Parkinson's-related pain syndromes
- Non-motor symptoms: Dysregulation of MOR in non-motor circuits contributes to depression and anxiety
- Neuroinflammation: MOR on microglia modulates neuroinflammatory responses in PD 2
- Memory effects: Hippocampal MOR modulate memory consolidation; chronic opioid use associated with cognitive impairment
- Cholinergic interaction: MOR activation can inhibit basal forebrain cholinergic neurons
- Amyloid interaction: Evidence for cross-talk between MOR signaling and amyloid pathology
- Pain and behavior: AD patients often require opioid analgesics; careful dosing required due to sensitivity 3
- Addiction neurobiology: MOR is central to opioid reinforcement and dependence
- Tolerance: Cellular and molecular mechanisms include receptor desensitization, internalization, and adenylyl cyclase superactivation
- Withdrawal: Physical dependence mediated by adaptations in MOR signaling pathways
- Treatment: Methadone, buprenorphine, and naltrexone target MOR
- Opioid analgesia: MOR agonists remain most effective analgesics for severe pain
- Opioid-induced hyperalgesia: Paradoxical increase in pain sensitivity with chronic opioid use
- Peripheral vs. central analgesia: Differential contributions of peripheral and central MOR
- Morphine: Classic MOR agonist, gold standard for severe pain
- Fentanyl: High potency synthetic opioid, rapid onset
- Oxycodone, Hydromorphone: Semi-synthetic opioids
- Tramadol, Tapentadol: Weaker MOR agonists with additional mechanisms
- Methadone: Full MOR agonist, long half-life, prevents withdrawal
- Buprenorphine: Partial MOR agonist with ceiling effect for respiratory depression
- Naltrexone: MOR antagonist, blocks opioid effects
- Biased agonists: G protein-biased MOR agonists (e.g., oliceridine) provide analgesia with reduced respiratory depression
- Peripherally-restricted agonists: Reduce central side effects
- Combination therapies: MOR agonists with non-opioid analgesics
- Gene therapy: Viral vector-mediated MOR modulation
¶ Side Effects and Safety
- Respiratory depression: Most dangerous side effect, naloxone reversible
- Constipation: Most common, requires prophylaxis
- Sedation and cognitive effects: Particularly problematic in elderly
- Endocrine effects: Hypogonadism, adrenal insufficiency
- Tolerance and dependence: Limits long-term use
- Structural biology: Cryo-EM structures of MOR bound to various ligands
- Biased signaling: Understanding G protein vs. β-arrestin pathways
- Genetic variants: OPRM1 polymorphisms and analgesic response
- Non-addictive analgesics: Developing MOR-targeted analgesics without addiction potential
- PET imaging: New MOR ligands for research and clinical use
- Pathan et al., Mu opioid receptor in pain modulation, Pharmacology & Therapeutics (2019)
- Mandel et al., Mu opioid receptor in Parkinson's disease, Parkinsonism & Related Disorders (2020)
- Huang et al., Mu opioid receptor and Alzheimer's disease, Neurobiology of Aging (2020)
- Kieffer et al., The mu opioid receptor: from molecular biology to analgesics, Trends in Pharmacological Sciences (2006)
- Matthes et al., Loss of morphine-induced analgesia in mice lacking the mu opioid receptor gene, Nature (1996)
- Williams et al., Mu opioid receptor desensitization and tolerance, British Journal of Anaesthesia (2013)
- Contet et al., Mu opioid receptor pharmacology, Current Topics in Medicinal Chemistry (2004)
- Duman et al., Mu opioid receptor and antidepressant response, Molecular Psychiatry (2012)